1 Medical Stock to Buy in February and 1 to Avoid Like the Plague

NASDAQ: NATR | Natures Sunshine Products, Inc. News, Ratings, and Charts

NATR – The medical industry is expected to grow due to increasing healthcare requirements and federal support. Moreover, given the inelastic demand for healthcare products and services, fundamentally strong medical stock Nature’s Sunshine Products (NATR) could be an ideal buy this month. However, SNDL (SNDL) might be best avoided, considering its weak fundamentals. Keep reading…

The medical industry is expected to thrive due to rising chronic diseases, an aging population, increased health awareness, rapid medication discovery, and technical advancements and trends. Moreover, government initiatives supporting the people are projected to help millions to overcome financial barriers and find proper treatments.

Furthermore, the industry’s growth is expected to be driven by expanding demand for home healthcare, rising disposable income, and advancements in home-care technologies. The home healthcare market is estimated to grow at a CAGR of 3.1% until 2033.

In addition, medical companies enjoy stable demand for their products and services irrespective of the macroeconomic scenario. Therefore, investors could consider buying quality medical stock, Nature’s Sunshine Products, Inc. (NATR). However, SNDL Inc. (SNDL) might be best avoided, considering its weak fundamentals.

Stock to Buy:

Nature’s Sunshine Products, Inc. (NATR)

Natural health and wellness company NATR primarily manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally.

NATR’s forward EV/Sales of 0.37x is 78.4% lower than the industry average of 1.72x. Its forward Price/Sales of 0.44x is 62% lower than the industry average of 1.19x.

NATR’s trailing-12-month gross profit margin of 71.59% is 127% higher than the industry average of 31.53%. Its trailing-12-month ROTA of 4.96% is 33% higher than the industry average of 3.73%.

NATR’s selling, general, and administrative expenses came in at $36.79 million for its third quarter ended September 30, 2022, down 6.9% year-over-year. Its total current liabilities came in at $63.89 million for the period ended September 30, 2022, compared to $76.67 million for the period ended December 31, 2021.

NATR’s revenue is expected to rise marginally year-over-year to $420.61 million in 2023. Its EPS is estimated to grow 280% year-over-year to $0.18 in 2023. Over the past three months, the stock has gained 10.1% to close the last trading session at $9.88.

NATR’s strong fundamentals are reflected in its POWR Ratings. The stock’s overall A rating indicates a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

NATR has an A grade for Value and Quality and a B for Stability and Sentiment. In the B-rated Medical – Consumer Goods industry, it is ranked first out of 9 stocks. Click here for the additional POWR Ratings for Growth and Momentum for NATR.

Stock to Avoid:

SNDL Inc. (SNDL)

Headquartered in Calgary, Canada, SNDL engages in the production, distribution, and sale of cannabis products, operating through the Cannabis Operations and Retail Operations segments.

SNDL’s trailing-12-month gross profit margin of 19.07% is 65.6% lower than the 55.48% industry average. Its trailing-12-month net income margin of negative 54.54% compares to the negative 5.61% industry average.

SNDL’s net loss for the fiscal third quarter that ended September 30, 2022, came in at C$98.84 million ($74.04 million) compared to the net earnings of C$16.71 million ($12.51 million) in the prior-year quarter. Its loss from operations came in at C$88.54 million ($66.32 million), up 365% year-over-year.

Also, its current asset came in at C$526.03 million ($394.01 million) for the period that ended September 30, 2022, compared to C$728.18 million ($545.42 million) for the period that ended December 31, 2021.

Analysts expect SNDL’s EPS to be negative $0.06 in 2023. The company missed EPS estimates in each of the trailing four quarters. Over the past month, the stock has lost 66.1% to close the last trading session at $2.07.

SNDL has an overall rating of D, which equates to Sell in our POWR Ratings system.

The stock has an F grade for Momentum and Stability and a D for Sentiment. In the D-rated Medical – Pharmaceuticals industry, SNDL is ranked #139 out of 174 stocks. For additional SNDL ratings for Growth, Value, and Quality, click here.

What To Do Next?

Get your hands on this special report:

7 SEVERELY Undervalued Stocks

The best part of the recent bear market is that there are thriving companies trading at tremendous discounts to fair value.

This combination of stellar earnings growth and low price provides a great catalyst for investor success.

And this report focuses on the 7 best of these stocks primed to soar in the weeks ahead. Click below to claim your copy now.

7 SEVERELY Undervalued Stocks


NATR shares were trading at $9.88 per share on Monday afternoon, up $0.24 (+2.49%). Year-to-date, NATR has gained 18.75%, versus a 6.49% rise in the benchmark S&P 500 index during the same period.


About the Author: Rashmi Kumari


Rashmi is passionate about capital markets, wealth management, and financial regulatory issues, which led her to pursue a career as an investment analyst. With a master's degree in commerce, she aspires to make complex financial matters understandable for individual investors and help them make appropriate investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
NATRGet RatingGet RatingGet Rating
SNDLGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Is This REALLY a Bull Market?

The S&P 500 (SPY) keeps making record highs...but does that mean that market conditions are truly bullish? 44 year investment veteran shines a light on how hollow recent gains are as they are only accruing to a handful of stocks with most investors searching high and low for stock market gains. Read on for more...

Unveiling Adobe (ADBE) Q2 Earnings: What Lies Ahead for Investors?

Software giant Adobe Inc. (ADBE) has released its second-quarter earnings, revealing double-digit growth in both revenue and profits. Yet, concerns arise around the complexities of navigating growth in the face of advancing AI technologies. Let’s analyze ADBE’s recent performance and assess key fundamentals to uncover what lies ahead for investors…

3 AI Stocks to Invest in for the Next Technological Revolution

The AI market is experiencing a significant growth trajectory, driven by widespread application across various industries. Hence, it could be wise to invest in top AI stocks, Alphabet (GOOGL), Meta Platforms (META), and Alibaba Group Holding (BABA) for the next technological revolution. Read more...

Analyzing Broadcom’s (AVGO) Q2 Earnings: Worth Investing?

Driven by a surge in demand for its AI products, Broadcom (AVGO) reported robust earnings in its latest quarterly results, exceeding expectations on both top and bottom lines. However, is the stock’s recent announcement of a 10-for-1 stock split worth investing in? Keep reading to find out…

Bullish or Bearish Stock Set Up?

The S&P 500 (SPY) record highs sounds pretty darn bullish on the surface. Yet as we dig below the surface there are some curious signals that point more Risk Off. This is especially true as we come into the next Fed meeting after a round of data that points to inflation still being too high...only further delaying the first rate cut. What does this all mean for stocks from here? Steve Reitmeister offers his latest views on the market outlook along with a preview of his top picks to stay on step ahead of the market. Read on for more...

Read More Stories

More Natures Sunshine Products, Inc. (NATR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NATR News